Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Reduce” by Analysts

Posted by on Jul 9th, 2026

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have earned an average recommendation of “Reduce” from the five brokerages that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $1.8333.

PACB has been the subject of several recent research reports. Zacks Research downgraded Pacific Biosciences of California from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 20th. Barclays increased their price objective on Pacific Biosciences of California from $1.00 to $1.50 and gave the stock an “underweight” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pacific Biosciences of California in a report on Tuesday, April 21st.

Check Out Our Latest Report on PACB

Institutional Trading of Pacific Biosciences of California

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning boosted its holdings in Pacific Biosciences of California by 245.9% in the 2nd quarter. Creative Planning now owns 175,690 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 124,893 shares during the period. Cetera Investment Advisers increased its holdings in shares of Pacific Biosciences of California by 10.1% during the second quarter. Cetera Investment Advisers now owns 104,725 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 9,617 shares during the period. Prudential Financial Inc. raised its position in shares of Pacific Biosciences of California by 73.0% in the second quarter. Prudential Financial Inc. now owns 35,684 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 15,062 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Pacific Biosciences of California by 60.0% in the second quarter. Invesco Ltd. now owns 839,340 shares of the biotechnology company’s stock valued at $1,041,000 after buying an additional 314,697 shares during the period. Finally, HUB Investment Partners LLC bought a new stake in shares of Pacific Biosciences of California in the second quarter valued at approximately $77,000.

Pacific Biosciences of California Stock Down 3.8%

Pacific Biosciences of California stock opened at $1.50 on Thursday. The company’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $1.63. The stock has a market cap of $465.90 million, a P/E ratio of -3.49 and a beta of 2.29. Pacific Biosciences of California has a twelve month low of $1.09 and a twelve month high of $2.73.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Pacific Biosciences of California had a negative return on equity of 571.06% and a negative net margin of 80.35%.The company had revenue of $37.18 million during the quarter, compared to analysts’ expectations of $39.94 million. Equities analysts anticipate that Pacific Biosciences of California will post -0.5 earnings per share for the current fiscal year.

About Pacific Biosciences of California

(Get Free Report)

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.

Featured Articles

Analyst Recommendations for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.